Tetrandrine Alleviates Cerebral Ischemia/reperfusion Injury by Suppressing NLRP3 Inflammasome Activation Via Sirt-1
Overview
Environmental Health
General Medicine
Authors
Affiliations
Background & Aims: Tetrandrine (Tet) has been reported to have anti-inflammatory effects and protect from the ischemic strokes. The NLRP3 inflammasome plays a key role in cerebral ischemia/reperfusion (I/R)-induced inflammatory lesions. However, the molecular mechanisms of Tet related to the progression of cerebral ischemia are still unclear. Therefore, the aim of this study was to investigate the possible effects of Tet on cerebral ischemia and the related mechanisms involved in NLRP3 inflammasome.
Methods: C57BL/6J mice used as a cerebral I/R injury model underwent middle cerebral artery occlusion (MCAO) for 2 h following reperfusion for 24 h. Tet (30 mg/kg/day, ) was administered for seven days and 30 min before and after MCAO. Their brain tissues were evaluated for NLRP3 inflammasome and Sirtuin-1 (Sirt-1) expression. An intracerebroventricular injection of Sirt-1 siRNA was administered to assess the activation of the NLRP3 inflammasome.
Results: Tet significantly reduced the neurological deficits, infarction volume, and cerebral water content in MCAO mice. Moreover, it inhibited I/R-induced over expression of NLRP3, cleaved caspase-1, interleukin (IL)-1β, IL-18, and Sirt-1. Sirt-1 knockdown with siRNA greatly blocked the Tet-induced reduction of neurological severity score and infarct volume, and reversed the inhibition of NLRP3 inflammasome activation.
Conclusion: Our results demonstrate that Tet has benefits for cerebral I/R injury, which are partially related to the suppression of NLRP3 inflammasome activation via upregulating Sirt-1.
Insights on exploring the therapeutic potential and structural modification of Tetrandrine.
Gong L, Liu H, Xu B, Yu T, Wang Y, Niu S Future Med Chem. 2024; 16(24):2687-2700.
PMID: 39606807 PMC: 11731063. DOI: 10.1080/17568919.2024.2432297.
Neuroprotective potential for mitigating ischemia-reperfusion-induced damage.
Ye Z, Liu R, Wang H, Zuo A, Jin C, Wang N Neural Regen Res. 2024; 20(8):2199-2217.
PMID: 39104164 PMC: 11759025. DOI: 10.4103/NRR.NRR-D-23-01985.
Kim D, Lee T, Ahn J, Yang S, Shin M, Cho J Mar Drugs. 2024; 22(4).
PMID: 38667787 PMC: 11050983. DOI: 10.3390/md22040170.
Zheng T, Jiang T, Huang Z, Ma H, Wang M Front Pharmacol. 2023; 14:1220862.
PMID: 37654609 PMC: 10467294. DOI: 10.3389/fphar.2023.1220862.
Research Progress on Neuroprotective Effects of Isoquinoline Alkaloids.
Li J, Wu Y, Dong S, Yu Y, Wu Y, Xiang B Molecules. 2023; 28(12).
PMID: 37375352 PMC: 10302352. DOI: 10.3390/molecules28124797.